River Road Asset Management LLC increased its stake in Taro Pharmaceutical Industries Ltd. (NYSE:TARO) by 33.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 65,470 shares of the company’s stock after buying an additional 16,350 shares during the period. River Road Asset Management LLC owned 0.16% of Taro Pharmaceutical Industries worth $7,337,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in TARO. Schwab Charles Investment Management Inc. boosted its position in shares of Taro Pharmaceutical Industries by 36.9% in the second quarter. Schwab Charles Investment Management Inc. now owns 4,850 shares of the company’s stock valued at $544,000 after buying an additional 1,306 shares during the period. Anchor Capital Advisors LLC boosted its position in shares of Taro Pharmaceutical Industries by 0.4% in the second quarter. Anchor Capital Advisors LLC now owns 20,733 shares of the company’s stock valued at $2,323,000 after buying an additional 77 shares during the period. Sei Investments Co. boosted its position in shares of Taro Pharmaceutical Industries by 7.7% in the second quarter. Sei Investments Co. now owns 8,372 shares of the company’s stock valued at $938,000 after buying an additional 597 shares during the period. Bessemer Group Inc. boosted its position in shares of Taro Pharmaceutical Industries by 138.6% in the second quarter. Bessemer Group Inc. now owns 2,083 shares of the company’s stock valued at $234,000 after buying an additional 1,210 shares during the period. Finally, Eagle Global Advisors LLC purchased a new position in shares of Taro Pharmaceutical Industries during the second quarter valued at approximately $616,000. Institutional investors and hedge funds own 14.25% of the company’s stock.

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) opened at 102.16 on Wednesday. The company has a 50-day moving average price of $109.76 and a 200 day moving average price of $112.65. The company has a market capitalization of $4.14 billion, a PE ratio of 10.40 and a beta of 0.64. Taro Pharmaceutical Industries Ltd. has a 12 month low of $92.28 and a 12 month high of $129.37.

COPYRIGHT VIOLATION WARNING: This report was first reported by Watch List News and is owned by of Watch List News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of United States & international trademark and copyright laws. The legal version of this report can be accessed at https://www.watchlistnews.com/taro-pharmaceutical-industries-ltd-taro-shares-bought-by-river-road-asset-management-llc/1531822.html.

Several brokerages recently commented on TARO. BidaskClub cut Taro Pharmaceutical Industries from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. TheStreet cut Taro Pharmaceutical Industries from a “b-” rating to a “c+” rating in a research report on Wednesday, August 9th. Finally, Credit Suisse Group cut Taro Pharmaceutical Industries from an “outperform” rating to a “neutral” rating in a research report on Tuesday, May 23rd.

Taro Pharmaceutical Industries Company Profile

Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc (Taro Canada) and Taro U.SA The Company markets over 200 pharmaceutical products in over 25 countries.

Institutional Ownership by Quarter for Taro Pharmaceutical Industries (NYSE:TARO)

Receive News & Ratings for Taro Pharmaceutical Industries Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.